The Correlation Between Pre-treatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters and Clinical Prognostic Factors in Pediatric Hodgkin Lymphoma

Pediatrık Hodgkin Lenfoma Hastalarında Tedavi Öncesi Florodeoksıglıkoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi Parametreleri ve Klinik Prognostik Faktörler Arasındaki İlişki

Ebru Tatçı¹, İnci Uslu Biner¹, Suna Emir², Hikmet Gülşah Tanyıldız³, Özlem Özmen¹, Engin Alağız⁴, Atıla Gökçek⁵, Gürses Şahin³

¹Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
²Ankara Children’s Hematology Oncology Training and Research Hospital, Department of Pediatric Hematology Oncology, Ankara, Turkey
³Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital, Department of Pediatric Oncology and Hematology, Ankara, Turkey
⁴Gülhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
⁵Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Radiology, Ankara, Turkey

Abstract

Objective: To compare standardized uptake values (SUV) derived from pre-treatment ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL).

Methods: Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study. Metabolic tumor volume (MTV), SUV\textsubscript{max} normalized by weight (SUV\textsubscript{weight}), lean body mass (SUV\textsubscript{lbm}), body surface area (SUV\textsubscript{bsa}) and plasma glucose levels of tumors (SUV\textsubscript{glucose}) were calculated using pre-treatment FDG PET/CT scan images. These metabolic parameters were correlated with clinical factors [age, sex, number of lymph node groups, presence of splenic involvement, bulky mediastinal disease, Ann Arbor stage, serum white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), serum albumin and hemoglobin levels].

Results: SUV\textsubscript{bsa}, SUV\textsubscript{lbm}, SUV\textsubscript{weight}, SUV\textsubscript{glucose} and MTV were higher in patients with stage III-IV disease, bulky tumor and ≥3 lymph node groups (p<0.05). SUV\textsubscript{bsa} and SUV\textsubscript{glucose} were higher in patients with splenic involvement (p<0.05). There was no significant correlation between these metabolic parameters and sex, ESR, levels of albumin and WBC (p>0.05). SUV\textsubscript{bsa}, SUV\textsubscript{lbm} and SUV\textsubscript{weight} were higher in patients with anemia (p<0.05). Additionally, significant increases were detected in SUV\textsubscript{weight}, MTV, and SUV\textsubscript{glucose} with increasing age (p=0.005, p=0.027, and p=0.009, respectively). SUV\textsubscript{bsa} and SUV\textsubscript{lbm} had no significant correlation with age (p>0.05).

Conclusion: Metabolic parameters derived from pre-treatment FDG PET/CT may have an important role in predicting high-risk disease in patients with HL. Also, SUV\textsubscript{bsa} and SUV\textsubscript{lbm} may be better markers than SUV\textsubscript{weight} in the quantitative evaluation of FDG PET/CT scans in pediatric patients.

Keywords: Fluorodeoxyglucose positron emission tomography/computed tomography, Hodgkin lymphoma, standardized uptake value, metabolic tumor volume

Address for Correspondence: Ebru Tatçı MD, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
Phone: +90 505 914 53 61 E-mail: ebrualkandr@yahoo.com Received: 26.07.2016 Accepted: 24.10.2016

©Copyright 2017 by Turkish Society of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy published by Galenos Yaynevi.
Introduction

Currently, more than 80% of patients with Hodgkin lymphoma (HL) can be cured by contemporary treatment methods. The present major problem with HL is the long-term complications of treatment. Children who have been treated for HL have a higher risk of developing secondary tumors, cardiac events, and infections (1). Prognostic factors are considered during treatment planning to decrease the side effects and the likelihood of recurrence or treatment resistance (2). The most unfavorable prognostic factors according to the International Prognostic Score are stage 4 disease, age ≥45 years, hemoglobin <10.5 g/dl, albumin <4.0 g/dl, white cell count (WBC) ≥15,000/µl, and lymphocyte count <600/µl or <8%, respectively. Also, presence of B symptoms, high erythrocyte sedimentation rate (ESR), male sex, higher number of involved nodal sites, and bulky-mass tumors are additional factors associated with an increased risk of relapse (3).

It has been reported in many studies that FDG PET-CT is a very useful imaging modality in the primary staging, restaging, assessment of treatment response and evaluation of residual masses of lymphomas (4,5,6,7). Standardized uptake value (SUV) is used traditionally for the definition of metabolic activity in FDG PET imaging. The patient’s body weight is usually employed as the body size measurement during the calculation of SUV. However, lean body mass or body surface area may be preferred for body size measurement by some authors. SUV is also affected by blood glucose level, post-injection uptake time, image resolution, image reconstruction parameters, and volume-of-interest-definition (8,9). Additionally, the maximum SUV (SUV_{max}) is only measured by the highest image pixel in the tumor regions and doesn’t show the metabolic activity of the entire tumor. Metabolic tumor volume (MTV) is another FDG PET/CT parameter, which is the measurement of the tumor volume with increased metabolism. It has been reported that MTV could play an important role in predicting survival in various malignancies (10,11). The purpose of this study was to evaluate the role of FDG-PET/CT in staging pediatric HL, and to establish if the metabolic parameters of pre-treatment FDG PET/CT correlated with clinical prognostic factors in pediatric HL patients. If so, metabolic parameters of pre-treatment FDG PET/CT might have a role in predicting treatment failure. Additionally, we evaluated the correlation of age and metabolic parameters in pediatric patients.

Materials and Methods

Patients

Twenty-eight HL patients who underwent pre-treatment FDG PET/CT examinations between May 2009 and December 2014 were included in this retrospective study. Informed consent was waived due to the retrospective nature of the study. Patients older than 18 years were excluded. The study was approved by the Institutional Ethics Committee. The histologic classifications were established according to the standard WHO classification scheme (12). Results of bone marrow biopsy (BMB), levels of WBC, albumin and hemoglobin values and ESR were recorded. After completion of therapy, patients were
followed by physical examination, laboratory analyses, chest radiographs, ultrasonography, CT or FDG PET/CT scans.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging

PET/CT imaging was performed forty-five to sixty minutes after intravenous injection of 87.69-414.77 MBq (2.37-11.21 mCi) of FDG with a Siemens Biograph 6 HI-REZ integrated PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA). All patients fasted for at least six hours before PET/CT imaging without water restriction. The blood glucose levels of patients were confirmed to be less than 180 mg/dL before FDG injection. Low-dose whole-body CT was used for attenuation correction. PET/CT data were acquired from the top of the skull to the upper thigh.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Analysis

Visual Analyses

Pre-treatment PET/CT images were retrospectively evaluated by two experienced nuclear medicine physicians and one radiologist. The number of lymph node groups was determined. A splenic FDG uptake greater than hepatic uptake was considered as splenic involvement. The marrow was considered as abnormal when the uptake was equal to or greater than that of the liver. Bulky disease was defined as presence of a lymph node mass greater than 0.33 of the maximum intrathoracic cavity width. The intensity of FDG activity within the bone marrow (BM) was evaluated visually. BMB results were used as the gold-standard for staging. The stage of lymphoma was assessed according to the Ann-Arbor classification (13).

Semi-quantitative Analyses

$SUV_{\text{max}}$ and MTV values were obtained from pre-treatment FDG PET/CT images for semi-quantitative evaluation. The $SUV_{\text{max}}$ corrected for body weight ($SUV_{\text{weight}}$) was measured within the hottest tumor lesion according to the formula (14):

$$SUV_{\text{weight}} = \frac{\text{Tissue concentration (MBq/ml)}}{\text{Injected dose (MBq)/ weight (g)}}$$

The $SUV_{\text{max}}$ normalized for lean body mass ($SUV_{\text{Ibm}}$), and body surface area ($SUV_{\text{bsa}}$) were calculated using the following equations (14):

$$SUV_{\text{Ibm}} = \frac{\text{Tissue concentration (MBq/ml)}}{\text{Injected dose (MBq)/ Ibm (kg)}}$$

$$SUV_{\text{bsa}} = \frac{\text{Tissue concentration (MBq/ml)}}{\text{Injected dose (MBq)/ BSA (m²)}}$$

$$\text{BSA (m²)} = 0.007184 \times \text{weight (kg)}^{0.425} \times \text{height (cm)}^{0.725}$$

$SUV_{\text{glucose}}$ values were also corrected for blood glucose level using an established formula, assuming a normal blood glucose level of 5.55 mmol/L (100 mg/dL) (14):

$$SUV_{\text{glucose}} = \frac{SUV_{\text{max}} \times \text{blood glucose (mmol/L)}}{5.55 \text{ mmol/L}}$$

MTV of each hypermetabolic tumor focus was automatically calculated by the software program and MTV of each tumor was summated. The threshold intensity value used in this study was 40% of maximal SUV of each tumor as validated in several previous studies (15,16).

Statistical Analyses

The SPSS 20 software was used for statistical analysis. Comparisons of SUV levels ($SUV_{\text{weight}}$, $SUV_{\text{bsa}}$, $SUV_{\text{Ibm}}$, $SUV_{\text{glucose}}$, MTV) and clinical parameters (sex, number of lymph node groups, presence of splenic involvement, bulky disease, Ann Arbor stage, serum levels of albumin, WBC, ESR and hemoglobin) were performed using the independent test or Mann-Whitney U test. All quantitative values are given as mean±standard deviation (SD). Pearson’s correlation coefficients were used to evaluate the correlation between PET parameters and age. A statistically significant difference was defined as a p value <0.05.

Results

Patients

The characteristics of the patients are presented in Table 1. A total of 28 patients with a mean age ±SD of 9.39±4.2 years (male/female: 17/11) were enrolled in this study. Eleven (39.3%) patients had nodular sclerosis subtype and 15 (53.6%) had mixed cellularity subtype. Histologic subtype remained unclassified in two patients. Of all 28 patients, 18 (64.2%) had undergone BMB.

The laboratory findings of the patients are summarized in Table 2. Among all 28 patients, hemoglobin was <10.5 g/dl in nine patients (32.1%), WBC was ≥15000/ml in 11 patients (39.3%), albumin was <4 g/dl in 16 patients
(57.1%), and ESR was ≥50 mm/hr in 13 patients (46.4%). All of the patients underwent three to six courses (6-12 cycles) of chemotherapy with or without radiation therapy after the initial PET/CT scanning. The mean±SD clinical follow-up period was 29±14 months. All 28 patients were in remission at the last follow up, but one child died of infection. Recurrence was not detected in the follow-up.

**Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Analyses**

**Visual Analyses**

Pre-treatment FDG PET/CT findings are summarized in Table 2. Bulky mediastinal disease was detected in 15 of the 28 (53.5%) patients. While there were <3 lymph node groups in 28.6% of the 28 patients (n=8), ≥3 lymph node groups were found in 71.4% (n=20). Splenic involvement was detected in 32.1% patients (n=9). Eight patients had stage 1-2 (28.6%) disease, and 20 patients had stage 3-4 (71.4%) disease.

Increased diffuse BM FDG uptake in the axial skeleton was seen in 12/28 (42.8%) patients. BMB was performed in 10 of these 12 (83.3%) patients. Among ten patients with diffuse BM uptake, nine patients had negative BMB results (Figure 1). Only one patient showed positive lymphoma involvement in BMB. There was no increase in BM FDG uptake in 16 of 28 (57.1%) patients. BMB was performed in seven of 16 (43.7%) whose BMB result was negative. Additionally radiolucency and enlargement at the localizations of ischiopubic synchondrosis (IPS) were detected in 4 of the 28 (14.2%) patients. Intense FDG uptakes were seen in these areas (SUV<sub>max</sub> range 1.17-3.10). These patients didn’t suffer from any symptoms such as groin pain and restriction in the movement of the hip joint.

Since these focal FDG uptakes weren’t identified in follow-up PET/CT scans, they were evaluated as the asymmetric ossification pattern of the IPS rather than malignant bone infiltration (Figure 2).

**Quantitative Analyses**

\[ \text{SUV}_{\text{bsa}}, \text{SUV}_{\text{lbm}}, \text{SUV}_{\text{weight}}, \text{SUV}_{\text{glucose}}, \text{and MTV} \] values were higher in patients with stage 3-4 disease, a bulky tumor, and ≥3 lymph node groups (p<0.05) (Table 2). \( \text{SUV}_{\text{bsa}} \) and \( \text{SUV}_{\text{glucose}} \) were higher in patients with splenic involvement (p<0.05). There was no significant correlation between metabolic parameters and a) sex, b) ESR, c) albumin level, and d) WBC level (p>0.05). Hemoglobin level lower than 10.5 g/dL was associated with higher \( \text{SUV}_{\text{bsa}} \) and \( \text{SUV}_{\text{lbm}} \) (p<0.05). While \( \text{SUV}_{\text{bsa}} \) and \( \text{SUV}_{\text{lbm}} \) did not relate to age; \( \text{SUV}_{\text{weight}}, \text{MTV} \), and \( \text{SUV}_{\text{glucose}} \) values were found to be significantly correlated with age (p=0.005, p=0.027, p=0.009 and r=0.519, r=0.506, r=0.504, respectively).

**Table 1. Patient characteristics**

| Characteristics      | n, (%)  |
|----------------------|---------|
| Sex M/F              |         |
| Male                 | 17 (60.7)|
| Female               | 11 (39.2)|
| Age, y (mean±SD)     | 9.39±4.2|
| Histological subtype |         |
| Nodular sclerosis    | 11/28 (39.3)|
| Mixed cellularity    | 15/28 (53.6)|
| Unclassified         | 2/28 (7.1)|
| Bone marrow biopsy   | 18/28 (64.2)|
| Therapy              |         |
| Chemotherapy         | 12/28 (42.8)|
| Chemoradiotherapy    | 16/28 (57.1)|

M: Male, F: Female, SD: Standard deviation
### Table 2. Fluorodeoxyglucose positron emission tomography/computed tomography parameters related to clinical prognostic factors

| Parameters                        | n   | SUV<sub>weight</sub> (mean±SD) | MTV (mean±SD) | SUV<sub>lbm</sub> (mean±SD) | SUV<sub>bsa</sub> (mean±SD) | SUV<sub>glucose</sub> (mean±SD) |
|-----------------------------------|-----|-------------------------------|---------------|-----------------------------|-----------------------------|-------------------------------|
| **Stage**                         |     |                               |               |                             |                             |                               |
| 1-2                               | 8   | 4.8±2.9                       | 56.2±45.3     | 1±0.4                       | 2±0.8                       | 5.8±2.1                       |
| 3-4                               | 20  | 10.8±4.5                      | 377.7±301.9   | 2±1.3                       | 3.9±1.3                     | 11.9±4.3                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.002                         | 0.012         | 0.006                       | 0.002                       | 0.001                         |
| **Bulky tumor**                   |     |                               |               |                             |                             |                               |
| Absent                            | 13  | 6.2±3.4                       | 162.2±206.4   | 1.2±0.8                     | 2.4±1.2                     | 6.8±2.8                       |
| Present                           | 15  | 11.6±4.7                      | 417.5±317.6   | 2.2±1.3                     | 4.2±1.3                     | 12.7±4.3                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.002                         | 0.032         | 0.034                       | 0.006                       | 0.001                         |
| **NLG**                           |     |                               |               |                             |                             |                               |
| <3                                | 8   | 5.6±3.2                       | 38.7±24.4     | 1.1±0.4                     | 2.4±0.9                     | 6.3±1.9                       |
| ≥3                                | 20  | 10.5±4.8                      | 360.9±299.4   | 1.9±1.3                     | 3.7±1.5                     | 11.4±4.7                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.014                         | 0.019         | 0.028                       | 0.037                       | 0.001                         |
| **Splemic involvement**           |     |                               |               |                             |                             |                               |
| Absent                            | 19  | 7.9±3.8                       | 225±189.5     | 1.6±1.2                     | 5±1.3                       | 8.6±3.9                       |
| Present                           | 9   | 11.7±6.1                      | 455.8±403.7   | 2.1±1.3                     | 4.2±1.6                     | 13.1±5.2                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.054                         | 0.106         | 0.327                       | 0.044                       | 0.23                          |
| **Sex**                           |     |                               |               |                             |                             |                               |
| Female                            | 11  | 8.1±3.9                       | 223±212.6     | 1.6±1                       | 3.2±1.2                     | 8.5±2.9                       |
| Male                              | 17  | 9.7±5.5                       | 341.1±325.4   | 1.9±1.3                     | 3.4±1.7                     | 11.1±5.5                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.387                         | 0.517         | 0.639                       | 0.736                       | 0.138                         |
| **Leukocyte count**               |     |                               |               |                             |                             |                               |
| <15000/ml                         | 17  | 8.4±4.2                       | 194.2±189.7   | 1.5±1                       | 3±1.5                       | 9.5±4.6                       |
| ≥15000/ml                         | 11  | 10.1±5.9                      | 438.7±353.8   | 2.1±1.5                     | 3.9±1.3                     | 10.7±5                        |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.4                            | 0.051         | 0.531                       | 0.159                       | 0.542                         |
| **Hemoglobin (g/dl)**             |     |                               |               |                             |                             |                               |
| ≥10.5                             | 19  | 8.5±5.3                       | 291.5±327.4   | 1.3±1                       | 2.9±1.4                     | 9.4±4.6                       |
| <10.5                             | 9   | 10.2±3.9                      | 361.8±221.6   | 2.6±1.2                     | 4.3±1.3                     | 11.4±4.7                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.21                           | 0.165         | 0.012                       | 0.028                       | 0.313                         |
| **ESR (mm/hr)**                   |     |                               |               |                             |                             |                               |
| <50                               | 15  | 8.8±5.8                       | 318±344.7     | 1.5±1.1                     | 3.2±1.4                     | 10.5±1.4                      |
| ≥50                               | 13  | 9.4±3.8                       | 296.3±223.4   | 1.9±1.3                     | 3.5±1.6                     | 10.4±4.4                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.779                         | 0.612         | 0.505                       | 0.632                       | 0.978                         |
| **Albumin (g/dl)**                |     |                               |               |                             |                             |                               |
| ≥4                                | 12  | 9.1±6.5                       | 410.5±398.3   | 1.3±1                       | 3.1±1.7                     | 9.6±5.5                       |
| <4                                | 16  | 9.1±3.5                       | 236.9±189.4   | 2±1.3                       | 3.5±1.4                     | 10.3±4.4                      |
| **p value**                       |     |                               |               |                             |                             |                               |
|                                   |     | 0.991                         | 0.221         | 0.178                       | 0.463                       | 0.717                         |

*NLG: Number of lymph node groups; SUV<sub>weight</sub>: Standardized uptake value normalized by weight, SUV<sub>lbm</sub>: Standardized uptake value normalized by lean body mass, SUV<sub>bsa</sub>: Standardized uptake value normalized by body surface area, SUV<sub>glucose</sub>: Standardized uptake value normalized by level of glucose, MTV: Metabolic tumor volume, SD: Standard deviation, ESR: Erythrocyte sedimentation rate*
Discussion

It was previously demonstrated in some studies in the literature that the amount of FDG accumulation is an important prognostic factor in various malignant tumors (17,18). Ceriani et al. (19) reported that elevated MTV was significantly associated with worse progression-free and overall survival in patients with primary mediastinal (thymic) large B-cell lymphoma. Suh et al. (20) showed that pre-treatment FDG PET could predict treatment response and survival outcomes in patients with extranodal natural killer/T-cell lymphomas of the head and neck. Similarly, we identified a significant association between quantitative FDG uptake and clinical prognostic factors in pediatric patients with HL. The quantitative parameters were higher in patients with stage 3-4 disease, a bulky tumor, and ≥3 lymph node groups (p<0.05), which are the clinical parameters that reflect tumor burden. Intensity of tumor cells is one of the most important parameters to determine the efficacy of treatment in HL (21). High SUV\textsubscript{max} and MTV can indicate poorer survival in patients with HL. Intensive therapy can be administered in these patients. However, in the presence of low FDG uptake, overtreatment can be avoided. The present study has several limitations. Cure was achieved in 27 of the 28 patients at the end of therapy and recurrence was not detected on follow-up. One child died of infection. So, progression-free survival and overall survival couldn’t be determined in this study.

Anemia, low albumin level, leukocytosis and high ESR level are particularly observed in advanced stage disease (3). HD is characterized by the presence of a low frequency of malignant cells known as Reed-Sternberg cells. The majority of the malignant tissues in HD constitutes a reactive cell infiltrate composed of variable proportions of lymphocytes, histiocytes, eosinophils, and plasma cells. Malignant Reed-Sternberg cells and reactive cells produce different cytokines. Close associations between elevation of cytokine levels in the plasma and presence of B symptoms, anemia, leukocytosis, high ESR and low serum albumin levels has been reported (22,23). Our study results indicate that hemoglobin level lower than 10.5 g/dL was associated with higher SUV\textsubscript{bsa} and SUV\textsubscript{lbm} (p<0.05). Higher SUV\textsubscript{bsa} and SUV\textsubscript{lbm} may be related to higher tumor burden and higher plasma cytokine levels. However, we did not observe significant correlation between metabolic parameters and ESR, levels of albumin and WBC (p>0.05). Long-term follow-up studies with a larger group of patients may yield more satisfactory results.

The amount of SUV\textsubscript{weight} changes was related to patient’s body weight. However, some reports show that SUV\textsubscript{lbm} and SUV\textsubscript{bsa} are less dependent on body weight than SUV\textsubscript{weight} (8,9). Concordant with these reports, our study showed that while SUV\textsubscript{weight}, MTV and SUV\textsubscript{glucose} increase with age (p<0.05), SUV\textsubscript{bsa} and SUV\textsubscript{lbm} did not significantly correlate with age (p>0.05). Changes with age can reduce the importance of SUV\textsubscript{weight}, MTV and SUV\textsubscript{glucose} values as markers to discriminate malignant tumors from benign ones in children. Also, these parameters can be misleading in evaluating therapy response. SUV\textsubscript{lbm} and SUV\textsubscript{bsa} may be preferred in the primary diagnosis, staging and follow up of malignancies in the pediatric population (24).

A diffuse homogeneous BM FDG uptake generally reflects hyperplastic BM caused by severe anemia, use of granulocyte colony stimulating factors, or chemotherapy. However, infiltration of tumor cells can also cause increased diffuse BM FDG uptake. Authors suggest that BMB is the gold standard in the staging of HL (25). However, focal FDG uptake can be adequate in the diagnosis of bone or BM involvement in HL (13). Nevertheless, physiologic FDG uptake patterns mimicking bone metastasis such as IPS should be taken into consideration while evaluating PET/CT scans in the pediatric population (26).

Conclusion

Metabolic parameters derived from pre-treatment FDG PET/CT scanning can be valuable in predicting high-risk disease in pediatric HL. Also, SUV\textsubscript{bsa} and SUV\textsubscript{lbm} might be better...
markers than SUV_{weight} in the quantitative evaluation of FDG PET/CT scans in pediatric patients. However, prospective studies with a larger group of patients are needed to obtain more reliable results.

Ethics

Ethics Committee Approval: The study were approved by the Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital of Local Ethics Committee. Informed Consent: Consent form was filled out by all participants. It was taken.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: Suna Emir, Hikmet Gülşah Tanyıldız, Gürses Şahin, Concept: Ebru Tatcı, Özlem Özmen, Design: Ebru Tatcı, Özlem Özmen, Data Collection or Processing: Ebru Tatcı, Inci Uslu Biner, Engin Alağöz, Suna Emir, Hikmet Gülşah Tanyıldız, Atıla Gökçek, Analysis or Interpretation: Ebru Tatcı, Özlem Özmen, Inci Uslu Biner, Literature Search: Ebru Tatcı, Writing: Ebru Tatcı.

Conflict of Interest: Authors declared no conflict-of-interest.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumele R, Crippa F, et al. Long-term results of combined chemotherapy/radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27-37.
2. Cardie P, Burgers JM, Henry-Amar M, Hayat M, Sizoo W, Van der Schueren E, Monconduit M, Noordijk EM, Lustman-Marechal T, Jang A, et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-252.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:1506-1514.
4. Tatsumi M, Miller JH, Wahl RL. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med 2007;48:1923-1931.
5. Delpas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Huot M. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31-38.
6. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET using 2-(18)F-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116.
7. Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelter T, Hajgaard L, Barrington S, Hain S, Lynch T, Hahn K. Guidelines for 18F-FDG PET and PET/CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008;35:1581-1588.
8. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195:310-320.
9. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDM: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164-167.
10. Sager S, Asa S, Yilmaz M, Uslu L, Vatankul B, Halaç M, Sönmezoglu K, Kannaz B. Prognostic significance and predictive performance of volume-based parameters of F-18 FDG PET/CT in squamous cell head and neck cancers. J Cancer Res Ther 2014;10:922-926.
11. Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol 2013;24:208-214.
12. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
13. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4:5.
14. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of 18F-FDG standardized uptake values in normal tissues. J Nucl Med 2004;45:784-788.
15. Schwartz DL, Harris J, Rosenthal DI, Opanowski A, Levering A, Ang KK, Trotti AM, Garden AS, Jones CU, Harari P, Foote R, Holland J, Zhang Q, Le QT. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys 2015;91:721-729.
16. Son SH, Kim DH, Hong CM, Kim CY, Jeong SY, Lee SW, Lee J, Ahn BC. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer 2014;14:585.
17. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF Jr, Lajkite JJ, Sculler JP. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
18. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73:1151-1157.
19. Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli E, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli E, Giovanella L, Johnson PW, Zucca E. Utility of baseline 18F-FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 2015;126:950-956.
20. Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, Lee JH, Jang YJ, Lee BJ. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008;49:1783-1789.
21. Specht L, Nordonstof AM, Cold S, Clausen NT, Nissen NI. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988;61:1719-1727.
22. Niens M, Visser L, Nolte IM, van der Steege G, Dieprastra A, Cordano P, Jarrett RF, Te Meerman GJ, Poppema S, van den Berg A. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2005;130:527-536.
23. Salgami EV, Efthathiou SP, Vlachakis V, Sekara EV, Syrigos KN, Roussou PP. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin’s lymphoma. Haematologica (Budap). 2002;32:377-387.
24. Meier JM, Alavi A, Iruvuri S, Alzeair S, Parker R, Houseni M, Johnson PW, Zucca E. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Chin Clin Oncol 2015;2:5.
25. Muzahir S, Mian M, Munir I, Khalid Nawaz M, Salman Faruqui Z, Aftab Mufti K, Bashir H, Uddin N, Siddiqui N, Maaz ALJ, Mahmood MT. Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in Hodgkin’s lymphoma. Br J Radiol 2012;85:e490-496.

26. Tsuji K, Tsuchida T, Kosaka N, Tanizawa A, Kimura H. Serial changes of (18)F-FDG PET/CT findings in ischiopubic synchondrosis: comparison with contrast-enhanced MRI. Hell J Nucl Med 2015;18:66-67.